Chairs: J.Y Blay, FR - P.G. Casali, IT - R. Stahel, CH
Rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. This Course is aimed at dealing with them on an annual basis with the ultimate goal to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence. This course has been conceived in the context of the European Reference Network on Rare Adult Solid Cancers (EURACAN) and the Joint Action on Rare Cancers of the European Union (JARC). The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with the networking activities of EURACAN and the networking educational efforts that are ongoing within EURACAN, JARC and Rare Cancers Europe.
The RARECARE project provided a definition and a list of rare cancers, the following being the 10 “families” of rare adult solid cancers:
• Rare skin cancers and non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Digestive rare cancers
• Rare urological and male genital tumors
• Central nervous system neoplasms
• Head and neck cancers
The third edition of this joint initiative, which involves ESO, ESMO and Rare Cancers Europe, will combine:
• Day 1 - Parallel Preceptorships on the majority of rare adult solid cancers. Participants will be invited to select 3 preceptorships they would like to attend.
• Day 2 and 3 - Clinical updates on the main innovations from the 10 families of rare adult solid cancers.
Preceptorships have been conceived by looking at the educational needs of clinical oncologists willing to open up to rare adult solid cancers as well as patient advocates. They will be multidisciplinary and clinically oriented.
The Clinical update sessions are designed to address the needs of oncologists wanting to catch up with the advancements in the treatment of rare adult solid cancers.
Attendees may select whether to attend all three days or only the 2-day Clinical Update.
|The course is an ESO-ESMO-RCE joint event|
|Held in collaboration with||In the framework of|
• Medical degree
• Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent
• Fluency in English
PATIENT ADVOCATES will be selected by Rare Cancers Europe. For information email@example.com
(From 1 November)
|Registration fee (Clinical Update - 2nd and 3rd day)||EUR 200||EUR 250
|Club ESO and ESMO Members (Clinical update)|| EUR 160
Rates are indicated in Euro and include VAT.
Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.
CANCELLATION OF REGISTRATION OR REPLACEMENT
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee minus handling charges of EUR 100 will be refunded within two months from notification, provided that the cancellation is received by ESO before 9 November. Communication of replacements will be possible up until 15 November.
Faculty - Programme and General information
FACULTY, PROGRAMME AND GENERAL INFORMATION
For all information please refer to this link.
|Save the event date:||01 December 2018|